Literature DB >> 25115163

Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study.

Piya Chaemsaithong1, Roberto Romero, Adi L Tarca, Steven J Korzeniewski, Alyse G Schwartz, Jezid Miranda, Ahmed I Ahmed, Zhong Dong, Sonia S Hassan, Lami Yeo, Tinnakorn Tinnakorn.   

Abstract

Objective: Fetuin-A is a negative acute phase protein reactant that acts as a mediator for lipotoxicity, leading to insulin resistance. Intravascular inflammation and insulin resistance have been implicated in the mechanisms of disease responsible for preeclampsia (PE). Maternal plasma concentrations of fetuin-A at the time of diagnosis of preterm PE are lower than in control patients with a normal pregnancy outcome. However, it is unknown if the changes in maternal plasma fetuin-A concentrations precede the clinical diagnosis of the disease. We conducted a longitudinal study to determine whether patients who subsequently developed PE had a different profile of maternal plasma concentrations of fetuin-A as a function of gestational age (GA) than those with uncomplicated pregnancies.
Methods: A longitudinal case-control study was performed and included 200 singleton pregnancies in the following groups: (1) patients with uncomplicated pregnancies who delivered appropriate for gestational age (AGA) neonates (n = 160); and (2) patients who subsequently developed PE (n = 40). Longitudinal samples were collected at each prenatal visit and scheduled at 4-week intervals from the first or early second trimester until delivery. Plasma fetuin-A concentrations were determined by ELISA. Analysis was performed using mixed-effects models.
Results: The profiles of maternal plasma concentrations of fetuin-A differ between PE and uncomplicated pregnancies. Forward analysis indicated that the rate of increase of plasma fetuin-A concentration in patients who subsequently developed PE was lower at the beginning of pregnancy (p = 0.001), yet increased faster mid-pregnancy (p = 0.0017) and reached the same concentration level as controls by 26 weeks. The rate of decrease was higher towards the end of pregnancy in patients with PE than in uncomplicated pregnancies (p = 0.002). The mean maternal plasma fetuin-A concentration was significantly lower in patients with preterm PE at the time of clinical diagnosis than in women with uncomplicated pregnancies (p < 0.05). In contrast, there were no significant differences in maternal plasma fetuin-A concentration in patients who developed PE at term. Conclusions: (1) The profile of maternal plasma concentrations of fetuin-A over time (GA) in patients who develop PE is different from that of normal pregnant women; (2) the rate of change of maternal plasma concentrations of fetuin-A is positive (increases over time) in the midtrimester of normal pregnancy, and negative (decreases over time) in patients who subsequently develop PE; (3) at the time of diagnosis, the maternal plasma fetuin-A concentration is lower in patients with preterm PE than in those with a normal pregnancy outcome; however, such differences were not demonstrable in patients with term PE.

Entities:  

Keywords:  hypertensive disorders in pregnancy; insulin resistance; intravascular inflammation; negative acute phase protein reactant; α2-Heremans–Schmid glycoprotein

Year:  2014        PMID: 25115163      PMCID: PMC5899046          DOI: 10.3109/14767058.2014.954242

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  193 in total

1.  Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling.

Authors:  Roxanna A Irani; Yujin Zhang; Cissy Chenyi Zhou; Sean C Blackwell; M John Hicks; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2010-03-29       Impact factor: 10.190

2.  A meta-analysis of tumor necrosis factor-alpha, interleukin-6, and interleukin-10 in preeclampsia.

Authors:  Cui Xie; Mian Zhi Yao; Jiang Bo Liu; Li Kuan Xiong
Journal:  Cytokine       Date:  2011-10-21       Impact factor: 3.861

3.  Predictive value of tumor necrosis factor alpha (TNF-alpha) in preeclampsia.

Authors:  Ibrahim Serdar Serin; Bülent Ozçelik; Mustafa Basbug; Hüseyin Kiliç; Derya Okur; Rusen Erez; Ybrahim Serdar Serin; Mustafa Bapbuo; Hüseyin Kýlýç
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2002-01-10       Impact factor: 2.435

Review 4.  Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension.

Authors:  Florian Herse; Babbette LaMarca
Journal:  Am J Reprod Immunol       Date:  2012-12-28       Impact factor: 3.886

5.  Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Francesca Gotsch; Jimmy Espinoza; Jyh Kae Nien; Luis Goncalves; Samuel Edwin; Yeon Mee Kim; Offer Erez; Juan Pedro Kusanovic; Beth L Pineles; Zoltan Papp; Sonia Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2008-01

Review 6.  Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia.

Authors:  R N Taylor; C J de Groot; Y K Cho; K H Lim
Journal:  Semin Reprod Endocrinol       Date:  1998

7.  Preeclampsia is associated with decreased serum alpha(2)-HS glycoprotein (fetuin-A) concentration.

Authors:  Attila Molvarec; László Kalabay; Zoltán Derzsy; András Szarka; Amrita Halmos; Balázs Stenczer; Philippe Arnaud; István Karádi; Zoltán Prohászka; János Rigó
Journal:  Hypertens Res       Date:  2009-05-29       Impact factor: 3.872

8.  Metabolic score as a novel approach to assessing preeclampsia risk.

Authors:  Rebecca M Mazar; Sindhu K Srinivas; Mary D Sammel; Christina M Andrela; Michal A Elovitz
Journal:  Am J Obstet Gynecol       Date:  2007-10       Impact factor: 8.661

9.  Enhanced thrombin generation in normal and hypertensive pregnancy.

Authors:  K de Boer; J W ten Cate; A Sturk; J J Borm; P E Treffers
Journal:  Am J Obstet Gynecol       Date:  1989-01       Impact factor: 8.661

10.  Hypertensive disorders and severe obstetric morbidity in the United States.

Authors:  Elena V Kuklina; Carma Ayala; William M Callaghan
Journal:  Obstet Gynecol       Date:  2009-06       Impact factor: 7.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.